-
Gut: Colon and rectal cancer survival rates in high-income countries
Time of Update: 2020-06-05
In a recent study published in Gut, an authoritative journal on digestive diseases, researchers aim to provide the latest estimates of the survival rates of colon and rectal cancer patients in seve
-
Blood: Glucocorticoids enhance anti-FLT3 mutation AML activity in FLT3 inhibitors
Time of Update: 2020-06-05
FLT3 is a gene with frequent mutations that are closely related to poor prognosis of acute myeloid leukemia (AML) Although most AML patients initially respond to FLT3 inhibitor therapy, they eventu
-
FDA approves CYRAMZA (ramucirumab) first-line treatment of metastatic EGFR mutation non-small cell lung cancer
Time of Update: 2020-06-05
About 50% of non-small cell lung cancer (NSCLC) patients had advanced or metastatic diseases at the time of first diagnosis, and the five-year survival rate in patients with metastatic NSCLC was 6%
-
Ibrance Co-Standard Therapy for Breast Cancer: Not Reaching Major End
Time of Update: 2020-06-05
Ibrance (Palbociclib) has failed to significantly improve disease-free survival (DFS) (DFS) when it comes to treating patients with hormone receptor (HR)-positive/HER2-negative early breast cancer,
-
Lancet respir med: Tepotinib combines gifitinib to treat EGFR-Met mutant non-small cell lung cancer
Time of Update: 2020-06-05
Tepotinib, a highly selective oral MET inhibitor, recently examined the efficacy and safety of Tepotinib-gifitinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC), who resisted EGFR
-
BMJ: Study on the risk of leaching breast cancer and breast cancer death in patients with breast catheter in situ cancer
Time of Update: 2020-06-05
Researchers recently examined the long-term risk of breast cancer and death from breast cancer after screening for breast catheterining in symfire (DCIS) study using NHS breast screening program
-
To starve cancer cells? Diettherapy is likely to be a short-term solution to cancer treatment!
Time of Update: 2020-06-05
The topic of what we should eat and what we should eat and what we should eat has been going on for a long time The Greeks and Romans once advocated a moderate diet as a way to live a long life Ove
-
PNAS: The team of Gao Guoquan of Zhongshan University found that metformin is effective against KRAS mutant colorectal cancer
Time of Update: 2020-06-05
For patients with metastatic colorectal cancer (mCRC), the overall survival rate was poor, especially in patients with KRAS tumor mutations, despite the use of Ilitocon or Osaliplatinum-based chemo
-
ASCO 2020 advanced urinary skin cancer has made new progress, Avelumab maintenance treatment combined BSC can extend the total survival period by 7.1 months!
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) is drawing to a close, and this academic feast has won the attention of oncologists around the world The most-watched sum
-
Nature and Immunity: Explain the process of depletion of T-cells and develop more effective immunotherapy
Time of Update: 2020-06-05
June 3, 2020 / bioON/bioON/ -- Mapping the life cycle of immune cells that have lost their vitality in the fight against cancer, giving researchers at the University of Pennsylvania School of Medic
-
Roche's Tecentriq/Avastin combination gets U.S. approval - the first immunotherapy for cancer that cannot be removed or metastatic
Time of Update: 2020-06-05
U.S regulators have approved a combination of Roche's PD-L1 monosero-tecentriq (atezolizumab) and anti-angiotherite-based monoserotrophilia monovastin (bevacionzumab) to treat unable to remove or m
-
China BiosimilarS Out of the Sea: Quto-Zhu single anti-biosimilar HLX02 received positive rating from CHMP
Time of Update: 2020-06-05
Shanghai Fuhong Hanxuan and Accord Healthcare Co., Ltd jointly announced that the European Medicines Agency (EMA) Human Medicines Committee (CHMP) has a positive opinion on the quto-bead monobiosim
-
NEJM: Oral Relugolix For Advanced Prostate Cancer
Time of Update: 2020-06-05
The oxyperolin injection is the standard drug for prostate cancer, and researchers recently examined the efficacy of the oral gonadotropin-releasing hormone antagonist Relugolix patients with ad
-
Recurrence of treatment or breakthrough for kidney cell carcinoma: FDA approves Tivozanib's NDA
Time of Update: 2020-06-05
Pharmaceutical company AVEO announced today that the U.S FDA has approved Tivozanib's new drug application (NDA) for the treatment of recurrent refractory renal cell carcinoma (RCC), the company's
-
Blood: IKAROS and CK2 regulate high-risk B-ALL BCL-XL expression and chemotherapy sensitivity
Time of Update: 2020-06-05
High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an invasive disease characterized by chemotherapy resistance A common feature of high-risk B-ALL is the loss of function of the tumor suppre
-
ASCO Frontiers . . . A summary of major breakthroughs in CAR-T therapy for relapse/incurable lymphoma
Time of Update: 2020-06-05
ASCO Frontiers Car-T therapy for recurrent/incurable lymphoma major breakthrough summary embedded antigen receptor T-cell therapy (chimeric antigen receptor T-celltherapy, CAR-T) as the more ef
-
ASCO 2020: HR-HER2-Advanced Breast Cancer Endolastal Metastay Treatment Options?
Time of Update: 2020-06-05
Primary drug resistance, visceral metastasis are the factors of poor prognosis of HR-HER2-advanced breast cancer, and are also difficult to overcome in individual endocrine therapy Previous studies
-
Liver Int: Gallstones Increase The Risk of Liver and Pancreatic Cancer! Kailua research nearly 80,000 people
Time of Update: 2020-06-05
Gallstones are common, and a recent study of nearly 80,000 people showed that gallstones increase the risk of gastrointestinal cancer studies showed that screening detected gallstones increased th
-
NEW DISCOVERY: ANTIMALARIAL DRUG PHENYLALCOHOL IS EXPECTED TO TREAT BRAIN TUMORS
Time of Update: 2020-06-05
Introduction: polymorphic glioblastoma is a type of glioma (GBM) and one of the most malignant brain tumors Glioma is the most common malignant tumor in the skull, accounting for 40 to 50 percent
-
ASCO 2020 Regret! Early local therapy failed to improve the overall survival rate of women with primary stage IV breast cancer
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) has been successfully concluded, and this academic feast has won the attention of oncologists around the world The most-w